Risk factors
ImmunityBio (IBRX) risk factors
Item 1A of every ImmunityBio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors81 risks4 new3 dropped18 reworded
New convertible notes and post-marketing study requirements for ANKTIVA add specific financial and regulatory risks.
Filed Feb 23, 2026 - FY2024 10-K risk factors80 risks
ImmunityBio relies heavily on commercializing its approved product ANKTIVA while managing significant debt and revenue interest obligations to Oberland and Dr. Soon-Shiong. The company faces manufacturing buildout risks, reliance on key personnel Dr. Soon-Shiong, and external supply shortages like TICE BCG.
Filed Mar 03, 2025